H
HaTay Pharmaceutical JSC
VN:DHT
HaTay Pharmaceutical JSC
VN:DHT
Price:
82 000
VND
2.37%
Market Closed
Market Cap:
6.8T
VND
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
DHT Alert
HaTay Pharmaceutical JSC
82000
+1900 (+2.37%)
| 52 Week Range |
22 100
82 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches VND.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
HaTay Pharmaceutical JSC
Balance Sheet
Balance Sheet Decomposition
HaTay Pharmaceutical JSC
HaTay Pharmaceutical JSC
| Current Assets | 810.2B |
| Cash & Short-Term Investments | 219.3B |
| Receivables | 143.5B |
| Other Current Assets | 447.5B |
| Non-Current Assets | 975B |
| Long-Term Investments | 16.5B |
| PP&E | 955.2B |
| Intangibles | 1.4B |
| Other Non-Current Assets | 1.9B |
| Current Liabilities | 593.1B |
| Accounts Payable | 147B |
| Accrued Liabilities | 25.5B |
| Short-Term Debt | 309.7B |
| Other Current Liabilities | 110.8B |
| Non-Current Liabilities | 141.6B |
| Long-Term Debt | 110.8B |
| Other Non-Current Liabilities | 30.8B |
Balance Sheet
HaTay Pharmaceutical JSC
HaTay Pharmaceutical JSC
Currency: VND
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
38 660
|
19 687
|
46 771
|
74 620
|
45 843
|
54 742
|
60 494
|
59 669
|
93 132
|
301 790
|
|
| Cash |
38 660
|
19 687
|
39 771
|
74 620
|
45 843
|
54 742
|
60 494
|
46 669
|
93 132
|
261 790
|
|
| Cash Equivalents |
0
|
0
|
7 000
|
0
|
0
|
0
|
0
|
13 000
|
0
|
40 000
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
350 000
|
53 000
|
80 000
|
|
| Total Receivables |
77 360
|
100 020
|
82 540
|
94 430
|
114 416
|
199 411
|
276 462
|
162 856
|
155 385
|
112 375
|
|
| Accounts Receivables |
67 925
|
90 061
|
77 193
|
86 943
|
87 095
|
186 489
|
249 858
|
121 112
|
109 915
|
87 350
|
|
| Other Receivables |
9 435
|
9 959
|
5 347
|
7 487
|
27 321
|
12 922
|
26 604
|
41 744
|
45 470
|
25 025
|
|
| Inventory |
157 010
|
219 727
|
323 650
|
401 584
|
406 821
|
383 880
|
396 434
|
434 762
|
709 420
|
514 507
|
|
| Other Current Assets |
23 515
|
33 397
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
296 546
|
372 831
|
452 961
|
570 634
|
567 079
|
638 033
|
733 390
|
1 007 287
|
1 010 937
|
1 008 673
|
|
| PP&E Net |
57 102
|
55 950
|
52 606
|
56 442
|
63 814
|
90 068
|
166 103
|
212 752
|
442 074
|
791 736
|
|
| PP&E Gross |
57 102
|
55 950
|
52 606
|
56 442
|
63 814
|
90 068
|
166 103
|
212 752
|
442 074
|
791 736
|
|
| Accumulated Depreciation |
149 649
|
159 326
|
170 143
|
184 247
|
193 523
|
201 008
|
193 014
|
201 922
|
218 302
|
232 413
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
1 377
|
2 027
|
1 810
|
1 593
|
1 377
|
|
| Note Receivable |
10
|
10
|
10
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
4 796
|
5 036
|
5 470
|
5 349
|
5 604
|
5 585
|
8 002
|
9 486
|
11 144
|
33 969
|
|
| Other Long-Term Assets |
1 610
|
2 738
|
2 920
|
2 274
|
2 627
|
3 157
|
10 525
|
6 256
|
3 754
|
2 510
|
|
| Total Assets |
360 063
N/A
|
436 565
+21%
|
513 967
+18%
|
634 709
+23%
|
639 124
+1%
|
738 220
+16%
|
920 046
+25%
|
1 237 591
+35%
|
1 469 502
+19%
|
1 838 264
+25%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
36 979
|
63 065
|
64 431
|
73 887
|
92 807
|
168 134
|
260 362
|
113 994
|
196 455
|
146 324
|
|
| Accrued Liabilities |
4 936
|
6 832
|
8 664
|
8 741
|
15 435
|
15 676
|
12 668
|
14 674
|
16 251
|
11 573
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
195 122
|
161 942
|
204 182
|
289 429
|
234 630
|
333 483
|
|
| Current Portion of Long-Term Debt |
102 095
|
155 859
|
168 587
|
227 452
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
30 912
|
38 041
|
66 543
|
66 476
|
55 308
|
75 407
|
88 249
|
60 982
|
115 806
|
104 609
|
|
| Total Current Liabilities |
202 790
|
263 797
|
308 225
|
376 556
|
358 673
|
421 159
|
565 460
|
479 079
|
563 143
|
595 988
|
|
| Long-Term Debt |
210
|
210
|
210
|
210
|
210
|
210
|
0
|
0
|
102 213
|
170 218
|
|
| Minority Interest |
24 148
|
26 387
|
26 054
|
26 209
|
26 152
|
23 412
|
23 386
|
23 580
|
25 499
|
28 877
|
|
| Other Liabilities |
1 620
|
2 407
|
3 184
|
3 753
|
4 242
|
4 705
|
4 973
|
5 167
|
5 306
|
4 908
|
|
| Total Liabilities |
228 768
N/A
|
292 801
+28%
|
337 673
+15%
|
406 728
+20%
|
389 276
-4%
|
449 486
+15%
|
593 819
+32%
|
507 825
-14%
|
696 161
+37%
|
799 992
+15%
|
|
| Equity | |||||||||||
| Common Stock |
62 826
|
62 826
|
62 826
|
125 637
|
188 448
|
211 274
|
211 274
|
264 088
|
264 088
|
823 418
|
|
| Retained Earnings |
16 643
|
27 139
|
46 745
|
63 217
|
47 356
|
48 883
|
71 385
|
68 298
|
71 082
|
88 257
|
|
| Additional Paid In Capital |
29 335
|
29 335
|
29 335
|
1 000
|
1 000
|
1 000
|
1 000
|
315 934
|
315 934
|
97 320
|
|
| Treasury Stock |
8 270
|
9 427
|
9 427
|
8 697
|
8 084
|
8 084
|
8 084
|
8 084
|
8 084
|
8 084
|
|
| Other Equity |
30 761
|
33 891
|
46 815
|
46 825
|
21 128
|
35 661
|
50 652
|
89 528
|
130 321
|
37 362
|
|
| Total Equity |
131 295
N/A
|
143 765
+9%
|
176 294
+23%
|
227 981
+29%
|
249 848
+10%
|
288 734
+16%
|
326 227
+13%
|
729 766
+124%
|
773 341
+6%
|
1 038 273
+34%
|
|
| Total Liabilities & Equity |
360 063
N/A
|
436 565
+21%
|
513 967
+18%
|
634 709
+23%
|
639 124
+1%
|
738 220
+16%
|
920 046
+25%
|
1 237 591
+35%
|
1 469 502
+19%
|
1 838 264
+25%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
21
|
21
|
21
|
21
|
21
|
21
|
59
|
74
|
74
|
82
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
